AVCRFPharmaceutical PreparationsFiscal year ends December 31
Avricore Health Inc.
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Jun 16, 2025
$0.00+0.00 (0.00%)
Close on Oct 16, 2026
Margins
Share of revenue, fiscal years 2014 to 2024
Gross margin
40.4%
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +33.7% | +236.0% | – | – | |
| Gross profit | +56.2% | +294.9% | +164.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on assets | – | -272.1% | – | |
| Capex to revenue | – | – | 3.9% | |
| Diluted shares | – | 47M | 100M |
Cash use needs five years of cash flow figures
Avricore Health does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 4 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zeroC$1.00M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net incomeC$1.00M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise100M → 100M
- Gross margin improvedGross margin up on the prior year34.54% → 40.36%
- More efficientAsset turnover rose1.36 → 1.84